Biori Biotechnology

Executive Summary

Biori Biotechnology is a private Chinese manufacturer of biological raw materials and reagent solutions for life science research, in vitro diagnostics (IVD), and biopharmaceutical applications. Founded in 2012 and based in Zhuhai, the company leverages protein engineering, recombinant expression, and process development to produce enzymes, master mixes, and reagents. Its focus is on enabling technologies for molecular diagnostics, next-generation sequencing, and mRNA/IVT workflows, rather than developing its own therapeutic drugs. With a commercial-stage business model and an employee range of 50–200, Biori serves as a critical supplier to the broader biotech and diagnostics ecosystem. The company's revenue is generated through product sales, and it benefits from the growing demand for raw materials in the life sciences sector, particularly in China and global markets. While not a high-risk biotech, its growth depends on expanding its customer base, launching new products, and maintaining competitive pricing and quality.

Upcoming Catalysts (preview)

• Q2 2027Expansion into new geographic markets (e.g., Southeast Asia, Europe)70% success
• Q4 2026Launch of new enzyme products for mRNA vaccine production60% success
• Q3 2026ISO certification or regulatory approvals for IVD reagents80% success